Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.49 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.48 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.48 |
| ▸ | FABP4 | P15090 | 1/20 | 0.47 |
| ▸ | HNF4A | P41235 | 1/20 | 0.44 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.44 |
| ▸ | KMO | O15229 | 2/20 | 0.44 |
| ▸ | SLC13A5 | Q86YT5 | 1/20 | 0.42 |
| ▸ | PPARG | P37231 | 1/20 | 0.42 |
| ▸ | PPARA | Q07869 | 1/20 | 0.42 |
| ▸ | TAS2R14 | Q9NYV8 | 2/20 | 0.41 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.41 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
| ▸ | PLK1 | P53350 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23908702 | 0.91 | ALDH1A1 (0.51) | ALDH1A1HPGDLTB4RLTB4R2FABP4 | |
| SCHEMBL6677946 | 0.86 | BCAT2 (0.49) | ALDH1A1HPGDFOLH1FABP4FFAR4 | |
| SCHEMBL6584244 | 0.86 | ALDH1A1 (0.43) | ALDH1A1HPGDFOLH1LTB4RLTB4R2 | |
| SCHEMBL11459853 | 0.86 | NR1H2 (0.49) | ALDH1A1HPGDFABP4FFAR4PPARG | |
| SCHEMBL29978674 | 0.86 | BCAT2 (0.49) | ALDH1A1HPGDFOLH1FABP4FFAR4 | |
| SCHEMBL28636307 | 0.86 | ALDH1A1 (0.45) | ALDH1A1HPGDFOLH1LTB4RLTB4R2 | |
| SCHEMBL504216 | 0.82 | CA12 (0.46) | ALDH1A1HPGDFABP4KMOTAS2R14 | |
| SCHEMBL593127 | 0.80 | FOLH1 (0.61) | ALDH1A1HPGDFOLH1FABP4HNF4A | |
| SCHEMBL29702020 | 0.79 | ALDH1A1 (0.43) | ALDH1A1HPGDFOLH1FABP4FFAR4 | |
| SCHEMBL16394743 | 0.78 | ALDH1A1 (0.42) | ALDH1A1HPGDKMOTAS2R14PLK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240389450-A1 | LIGHT EMITTING ELEMENT, PRODUCTION METHOD FOR LIGHT EMITTING ELEMENT, DISPLAY DEVICE, AND PRODUCTION METHOD FOR DISPLAY DEVICE | Sharp Display Technology Corporation (JP) | 2024-11-21 | — | — | US | claimed |
| WO-2023079616-A1 | LIGHT EMITTING ELEMENT, PRODUCTION METHOD FOR LIGHT EMITTING ELEMENT, DISPLAY DEVICE, AND PRODUCTION METHOD FOR DISPLAY DEVICE | シャープディスプレイテクノロジー株式会社 | 2023-05-11 | — | — | WO | claimed |
| US-20240389450-A1 | LIGHT EMITTING ELEMENT, PRODUCTION METHOD FOR LIGHT EMITTING ELEMENT, DISPLAY DEVICE, AND PRODUCTION METHOD FOR DISPLAY DEVICE | Sharp Display Technology Corporation (JP) | 2024-11-21 | — | — | US | disclosed |
| WO-2023079616-A1 | LIGHT EMITTING ELEMENT, PRODUCTION METHOD FOR LIGHT EMITTING ELEMENT, DISPLAY DEVICE, AND PRODUCTION METHOD FOR DISPLAY DEVICE | シャープディスプレイテクノロジー株式会社 | 2023-05-11 | — | — | WO | disclosed |
| EP-2470498-A1 | CARBOCYCLIC GLYT1 RECEPTOR ANTAGONISTS | F. Hoffmann-La Roche AG (CH) | 2012-07-04 | — | — | EP | disclosed |
| US-20120016152-A1 | Process for the preparation of 4`-haloalkylbiphenyl-2-carboxylic acids | SALTIGO GMBH (DE) | 2012-01-19 | — | — | US | disclosed |
| EP-2391603-A1 | AROYLAMINO - AND HETEROAROYLAMINO-SUBSTITUTED PIPERIDINES AS GLYT-1 INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2011-12-07 | — | — | EP | disclosed |
| WO-2011023667-A1 | CARBOCYCLIC GLYT1 RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-03-03 | — | — | WO | disclosed |
| WO-2010086251-A1 | AROYLAMINO - AND HETEROAROYLAMINO-SUBSTITUTED PIPERIDINES AS GLYT-1 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-08-05 | — | — | WO | disclosed |
| EP-2094643-A2 | N-((3-BENZYL)-2,2-(BIS-PHENYL)-PROPAN-1-AMINE DERIVATIVES AS CETP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROSIS AND CARDIOVASCULAR DISEASES | Brystol-Myers Squibb Company (US) | 2009-09-02 | — | — | EP | disclosed |
| EP-2010170-A2 | USE OF BIARYLCARBOXAMIDES IN THE TREATMENT OF HEDGEHOG PATHWAY-RELATED DISORDERS | Novartis AG (CH) | 2009-01-07 | — | — | EP | disclosed |
| EP-1326835-A1 | BENZAMIDE COMPOUNDS AS APO B SECRETION INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-07-16 | — | — | EP | disclosed |
| EP-1317431-A2 | POLYARYLCARBOXAMIDES USEFUL AS LIPID LOWERING AGENTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2003-06-11 | — | — | EP | disclosed |
| WO-2002090347-A1 | AMIDE COMPOUNDS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-11-14 | — | — | WO | disclosed |
| WO-2002028835-A1 | BENZAMIDE COMPOUNDS AS APO B SECRETION INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-04-11 | — | — | WO | disclosed |
| WO-2002020501-A2 | POLYARYLCARBOXAMIDES USEFUL AS LIPID LOWERING AGENTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2002-03-14 | — | — | WO | disclosed |
| US-20010034459-A1 | Process for preparing 4'-trifluoromethyl-2-methylbiphenyl and 4'-trifluoromethyl-biphenyl-2-carboxylic acid from o-tolylmetallates | MEUDT ANDREAS (DE) | 2001-10-25 | — | — | US | disclosed |
| EP-0832069-A1 | BIPHENYL-2-CARBOXYLIC ACID-TETRAHYDRO-ISOQUINOLIN-6-YL AMIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS INHIBITORS OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN AND/OR APOLIPOPROTEIN B (Apo B) SECRETION | PFIZER INC. (US) | 1998-04-01 | — | — | EP | disclosed |
| WO-1996040640-A1 | BIPHENYL-2-CARBOXYLIC ACID-TETRAHYDRO-ISOQUINOLIN-6-YL AMIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS INHIBITORS OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN AND/OR APOLIPOPROTEIN B (Apo B) SECRETION | PFIZER INC. (US) | 1996-12-19 | — | — | WO | disclosed |
| WO-1996022295-A9 | TRICYCLIC BENZAZEPINE VASOPRESSIN ANTAGONISTS | — | 1996-11-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010034459-A1 | Process for preparing 4'-trifluoromethyl-2-methylbiphenyl and 4'-trifluoromethyl-biphenyl-2-carboxylic acid from o-tolylmetallates | ZC3HAV1L, ZRANB2, ZFP3 | ALDH1A1 1678/4885HPGD 4158/4885FOLH1 4286/4885 |
| US-20120016152-A1 | Process for the preparation of 4`-haloalkylbiphenyl-2-carboxylic acids | CYP4B1, HACL2, UGT1A4 | ALDH1A1 110/4885HPGD 1495/4885FOLH1 1070/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.